Acronym:
GALAHAD
ACTRN/NCT /ethics:
NCT02854436
Scientific title:
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Summary of trial and patient characteristics
| Cancer Type | Prostate | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Prostate |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
| Sex | Male | Anticipated Start Date | 2016-08-31 |
| Molecular Target | Anticipated End Date | 2019-10-10 | |
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Male |
| Molecular Target | |
| Tumour Stream | Prostate |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2016-08-31 |
| Anticipated End Date | 2019-10-10 |
Trial Summary
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies
Lay Summary
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Sponsor / Cooperative group
Janssen Research & Development LLC
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Ashford Cancer Centre Research | Helen Daykin | hdaykin@adelaidecancercentre.com.au | 08 8292 2240 | Recruiting |